Original Research

Outcomes of Treatment with Recombinant Tissue Plasminogen Activator in Patients Age 80 Years and Older Presenting with Acute Ischemic Stroke

Journal of Clinical Outcomes Management. 2015 February;22(2)

References

1. US Census Bureau. Annual estimates of the resident population for selected age groups by sex for the United States, States, Counties, and Puerto Rico Commonwealth and Municipios: April 1, 2010 to July 1, 2013. Accessed at www.census.gov/popest/index.html.

2. Fang MC, Cutler DM, Rosen AB. Trends in thrombolytic use for ischemic stroke in the United States. J Hosp Med 2010;5:406–9.

3. Marini C, Baldassarre M, Russo T, et al. Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study. Neurology 2004;62:77–81.

4. Sylaja PN, Cote R, Buchan AM, Hill MD. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry 2006;77:826–9.

5. Heitsch LE, Panagos PD. Treating the elderly stroke patient: complications, controversies, and best care metrics. Clin Geriatr Med 2013;29:231–55.

6. Engelter ST, Bonati LH, Lyrer PA. Intravenous thrombolysis in stroke patients of > or = 80 versus < 80 years of age--a systematic review across cohort studies. Age Ageing 2006;35:572–580.

7. Forti P, Maioli F, Procaccianti G, et al. Independent predictors of ischemic stroke in the elderly: prospective data from a stroke unit. Neurology 2013;80:29–38.

8. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTischemic stroke, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768–74.

9. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581–7.

10. Sung PS, Chen CH, Hsieh HC, et al. Outcome of acute ischemic stroke in very elderly patients: is intravenous thrombolysis beneficial? Eur Neurol 2011;66:110–6.

11. Saposnik G, Guzik AK, Reeves M, et al. Stroke prognostication using age and NIH Stroke Scale: SPAN-100. Neurology 2013;80:21–8.

12. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997;28:2119–25.

13. Sandercock P, Wardlaw JM, Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012;379:2352–63.

14. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997;28:2109–18.

15. Bray BD, Campbell J, Hoffman A, et al. Stroke thrombolysis in England: an age stratified analysis of practice and outcome. Age Ageing 2013;42:240–5.

16. Kono S, Deguchi K, Morimoto N, et al. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. J Stroke Cerebrovasc Dis 2013;22:1175–83.

17. Berrouschot J, Rother J, Glahn J, et al. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients. Stroke 2005;36:2421–5.

18. Emberson J, Lees KR, Lyden P, et al; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014;384:1929–35.